Skip to content
ClinCalc Pro
Menu
Heart Failure

Sodium Zirconium Cyclosilicate

Brand names: Lokelma

Used in: Hyperkalaemia

Sodium zirconium cyclosilicate is an oral non-absorbed potassium-binding agent used to treat hyperkalaemia, including in patients with heart failure or chronic kidney disease where renin-angiotensin inhibitors are desirable.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It is an insoluble inorganic cation exchanger that selectively traps potassium ions in exchange for hydrogen and sodium throughout the gastrointestinal tract, increasing faecal potassium excretion and lowering serum potassium.

Prescribing in practice

  • It is not for emergency life-threatening hyperkalaemia because the onset is too slow — use established acute measures first and reserve this agent for ongoing control.
  • It can bind co-administered oral drugs with pH-dependent solubility, so separate other oral medicines from it in time as advised in the SPC.
  • Each dose adds a sodium load, which warrants caution in heart failure, hypertension or fluid overload, and it may cause oedema.

Monitoring

Monitor serum potassium during initiation and dose adjustment and periodically thereafter, watching also for hypokalaemia and signs of fluid retention.

Counselling the patient

  • Take other oral medicines separated in time from this binder as instructed.
  • Report ankle swelling or new breathlessness, which may indicate fluid retention.
  • Attend for the blood tests used to adjust your dose.

Evidence & guidelines

Randomised trials (HARMONIZE and related studies) demonstrated dose-dependent reductions in serum potassium and maintenance of normokalaemia, supporting its use for chronic hyperkalaemia management.

Reference: DIALIZE trial NEJM 2019; 380(18):1707-1716; NICE TA599; MHRA 2018; ESC HF Guidelines 2021; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.